Phase I study of CKD-516, a novel vascular disrupting agent, in patients with advanced solid tumors

Cancer Research and Treatment

Volumn 48, Issue 1, 2016, Pages 28-36

  Oh, Do Youn ^a,b   Kim, Tae Min ^a,b   Han, Sae Won ^a,b   Shin, Dong Yeop ^a,c   Lee, Yun Gyoo ^a,d   Lee, Keun Wook ^e   Kim, Jee Hyun ^e   Kim, Tae You ^a,b   Jang, In Jin ^a   Lee, Jong Seok ^e   Bang, Yung Jue ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Korea Cancer Center Hospital   (South Korea)

^d Samsung Medical Center   (South Korea)

^e Seoul National University Bundang Hospital   (South Korea)

Author keywords

CKD 516; Phase I clinical trial, Solid tumor; Vascular disrupting agent

Indexed keywords

ANTIHYPERTENSIVE AGENT; CKD 516; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; ANTINEOPLASTIC AGENT; BENZOPHENONE DERIVATIVE; N-(4-(3-(1H-1,2,4-TRIAZOL-1-YL)-4-(3,4,5-TRIMETHOXYBENZOYL)PHENYL)THIAZOL-2-YL)-2-AMINO-3-METHYLBUTANAMIDE; VALINE;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BONE CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ESOPHAGUS CANCER; FATIGUE; FEMALE; FEVER; HEART CANCER; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; MALE; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PHARMACOKINETICS; PROGRESSION FREE SURVIVAL; SINUS TACHYCARDIA; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; THYROID CANCER; UTERINE CERVIX CANCER; VOMITING; ADULT; AGED; ANALOGS AND DERIVATIVES; BLOOD VESSEL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM; PHASE 1 CLINICAL TRIAL; VASCULARIZATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZOPHENONES; BLOOD VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; VALINE;

EID: 84957541113     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2014.258     Document Type: Article

References (19)

1. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010;9:790-803.
2. Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumorvascular disrupting agents. Cancer Treat Rev. 2011;37:63-74.
3. Sessa C, Lorusso P, Tolcher A, Farace F, Lassau N, Delmonte A, et al. Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors. Clin Cancer Res. 2013;19:4832-42.
4. Eskens FA, Tresca P, Tosi D, Van Doorn L, Fontaine H, Van der Gaast A, et al. A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours. Br J Cancer. 2014;110: 2170-7.
5. Li J, Jamin Y, Boult JK, Cummings C, Waterton JC, Ulloa J, et al. Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography. Br J Cancer. 2014;110:1727-32.
6. Lee J, Kim SJ, Choi H, Kim YH, Lim IT, Yang HM, et al. Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. J Med Chem. 2010;53:6337-54.
7. Lee J, Bae S, Lee SH, Choi H, Kim YH, Kim SJ, et al. Discovery of a potent tubulin polymerization inhibitor: synthesis and evaluation of water-soluble prodrugs of benzophenone analog. Bioorg Med Chem Lett. 2010;20:6327-30.
8. Moon CH, Lee SJ, Lee HY, Dung le TK, Cho WJ, Cha H, et al. CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model. Invest New Drugs. 2014;32: 400-11.
9. Kim YI, Kim KW, Lee HK, Park J, Chung JW, Youn H, et al. Enhanced efficacy of CKD-516 in combination with doxorubicin: pre-clinical evaluation using a hepatocellular carcinoma xenograft model. Anticancer Res. 2014;34:1715-22.
10. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol. 2003;21:2815-22.
11. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol. 2003;21:4428-38.
12. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002;62:3408-16.
13. Beerepoot LV, Radema SA, Witteveen EO, Thomas T, Wheeler C, Kempin S, et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol. 2006;24:1491-8.
14. Mita MM, Spear MA, Yee LK, Mita AC, Heath EI, Papadopoulos KP, et al. Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas. Clin Cancer Res. 2010;16:5892-9.
15. Hande KR, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H, et al. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res. 2006;12:2834-40.
16. Joo I, Lee JM, Han JK, Choi BI. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors. Radiology. 2014;272:417-26.
17. Joo I, Kim JH, Lee JM, Choi JW, Han JK, Choi BI. Early quantification of the therapeutic efficacy of the vascular disrupting agent, CKD-516, using dynamic contrast-enhanced ultra-sonography in rabbit VX2 liver tumors. Ultrasonography. 2014;33:18-25.
18. Kim KW, Lee JM, Jeon YS, Kang SE, Baek JH, Han JK, et al. Free-breathing dynamic contrast-enhanced MRI of the abdomen and chest using a radial gradient echo sequence with K-space weighted image contrast (KWIC). Eur Radiol. 2013;23: 1352-60.
19. Baguley BC. Preclinical efficacy of vascular disrupting agents in non-small-cell lung cancer. Clin Lung Cancer. 2011;12:81-6.